Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | CACNA1H | O95180 | 8/20 | 0.38 |
| ▸ | LIPC | P11150 | 1/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.36 |
| ▸ | KIT | P10721 | 3/20 | 0.36 |
| ▸ | FLT3 | P36888 | 3/20 | 0.36 |
| ▸ | CACNA1G | O43497 | 6/20 | 0.34 |
| ▸ | CES2 | O00748 | 2/20 | 0.34 |
| ▸ | CCR2 | P41597 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | CAMK1D | Q8IU85 | 1/20 | 0.33 |
| ▸ | PSMB11 | A5LHX3 | 1/20 | 0.33 |
| ▸ | PSMA7 | O14818 | 1/20 | 0.33 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.33 |
| ▸ | PSMA1 | P25786 | 1/20 | 0.33 |
| ▸ | PSMA2 | P25787 | 1/20 | 0.33 |
| ▸ | PSMA3 | P25788 | 1/20 | 0.33 |
| ▸ | PSMA4 | P25789 | 1/20 | 0.33 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.33 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4552088 | 1.00 | ROCK2 (0.39) | ROCK2CACNA1HLIPCLIPGKIT | |
| Hydrochloric Acid SCHEMBL6873433 | 0.72 | MCHR1 (0.61) | KITFLT3 | |
| SCHEMBL28657037 | 0.71 | LIPG (0.49) | LIPCLIPGCES2PSMB11PSMA7 | |
| SCHEMBL23301178 | 0.68 | CES2 (0.46) | CES2 | |
| SCHEMBL14880120 | 0.68 | CES2 (0.50) | CES2 | |
| SCHEMBL5671522 | 0.68 | ROCK2 (0.42) | ROCK2CES2BTK | |
| SCHEMBL2492700 | 0.67 | CASP1 (0.47) | CES2 | |
| SCHEMBL3889815 | 0.65 | LMNA (0.52) | TACR1 | |
| SCHEMBL3889819 | 0.65 | LMNA (0.52) | TACR1 | |
| SCHEMBL3895469 | 0.65 | LMNA (0.52) | TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298834-A1 | 4-(AMINOMETHYL)CYCLOHEXANAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298834-A1 | 4-(AMINOMETHYL)CYCLOHEXANAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1I, CACNA1H | ROCK2 3534/4885CACNA1H 3/4885LIPC 4006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.